WALTHAM, MA – October 21, 2026 (STL.News) Ardelyx Inc. (NASDAQ: ARDX), a Massachusetts-based biopharmaceutical company, is facing a federal securities class action lawsuit alleging that the company and certain executives misled investors about its commercial growth prospects, prescription reimbursement challenges, and projected revenue from two pharmaceutical products. The lawsuit follows a nearly 18% decline in Ardelyx’s stock price on August 7, 2026, after the company reduced its annual revenue guidance for IBSRELA and withdrew long-term revenue projections for XPHOZAH. On October 21, 2026, securities litigation firm Levi & Korsinsky LLP issued another investor notice concerning the pending lawsuit, reminding
Source: Read Original Article